Ann: Updated guidance for PAT-DX1 phase 1 clinical study, page-126

When one sees the tear that ALA is on and that it appears that ALA are less advanced than PAB as ALA is yet to have attempted GMP at scale for clinical trial then it brings home the extent that the manufacturing stuff up has cost PAB.

But what ALA appears to have in their corner is a named partner in IMU that is giving street cred to their endeavors and potential investors something to pin their hopes on.

So it might be about time that the so called "good Dr" starts name dropping a few of these potential partners who are supposedly hiding in the shadows.